GeneDx Holdings Corp Stock Price, News & Analysis

GeneDx (WGS), a genomic insights company, has announced the granting of 46,340 restricted stock units (RSUs) to ten newly-hired employees as employment inducement awards. The grants, effective March 15, 2025, were approved by the compensation committee under GeneDx's 2023 Equity Inducement Plan and comply with Nasdaq Listing Rule 5635(c)(4).

The RSUs will vest equally over a four-year period, contingent on continued employment. Each RSU represents the right to receive one share of GeneDx's Class A Common Stock upon settlement. The company specializes in rare disease diagnostics, offering exome and genome tests to enable personalized healthcare solutions.

GeneDx (WGS) has been named one of Fast Company's World's Most Innovative Companies of 2025, ranking No. 2 in the Biotech category. The company is recognized for revolutionizing whole genome sequencing (WGS) with turnaround times as fast as 48 hours.

The company is leading innovation in genomic newborn screening (gNBS) through their GUARDIAN study, the largest of its kind examining gNBS in diverse newborn populations. GeneDx's screening capabilities now cover over 450 actionable genetic conditions that traditional newborn screening methods typically miss.

With 25 years of experience, GeneDx focuses on delivering early genetic disease diagnosis and improving healthcare outcomes through genomic insights. Their approach aims to transform healthcare delivery by identifying conditions before symptoms appear, potentially reducing healthcare system burden and improving patient outcomes.

GeneDx (WGS) announced its upcoming presentations at the 2025 American College of Medical Genetics and Genomics (ACMG) Annual Meeting, showcasing its genomic research and innovation through three platform presentations and two poster presentations.

The company will present its AI-powered gene ranker Multiscore, which prioritizes genes with positive findings in exome and genome sequences by analyzing patient clinical data. This tool aims to accelerate analysis, reduce turnaround times, and lower costs for patients.

Additionally, GeneDx will present findings from an RNA sequencing program for variant of uncertain significance (VUS) resolution, and showcase collaborations with PacBio, GUARDIAN, and Seqfirst. The research presentations include studies on HiFi sequencing applications, expanded newborn screening, and parental needs during pediatric whole genome sequencing.

GeneDx (WGS) has unveiled Multiscore, an advanced AI-powered decision support tool integrated into their genetic interpretation platform. The tool aims to revolutionize genetic analysis by improving diagnostic efficiency and streamlining workflows.

Multiscore leverages GeneDx's proprietary dataset of 750,000 clinical exome and genome sequences and over six million phenotypic datapoints, combined with publicly available data. The AI tool prioritizes genes in exome and genome sequences by ranking them based on patient clinical presentation, enabling faster and more accurate identification of genetic conditions.

The technology will be presented at the American College of Medical Genetics and Genomics (ACMG) Annual Meeting. By incorporating phenotypic similarities into gene ranking criteria, the tool helps identify pathogenic diagnoses even in complex cases where symptoms may not match textbook descriptions, ultimately reducing manual review time and accelerating result delivery.

GeneDx (Nasdaq: WGS) has expanded its genetic testing services to include cerebral palsy (CP) as a new indication during Cerebral Palsy Awareness Month. The company's research shows that approximately 300 genes are associated with CP, with genetic conditions identified as the underlying cause in nearly 1 in 3 CP patients.

The expansion aims to improve access to exome and genome testing for CP patients, which affects approximately 10,000 children annually. Recent data published by GeneDx in JAMA demonstrated a more than 30% diagnostic rate in a cohort of over 1,300 CP patients.

The company's testing can help guide personalized treatment strategies, identify eligibility for targeted therapies, and connect patients with advocacy groups. GeneDx has also established a collaboration with Geisinger to create a large-scale harmonized dataset for gene discovery and additional research in CP.

GeneDx (Nasdaq: WGS) announced the publication of the Seqfirst-neo study results in the American Journal of Human Genetics, conducted with Seattle Children's and the University of Washington. The study introduces a new approach using exclusion criteria for rapid genome sequencing (rGS) in NICU settings, demonstrating that at least 60% of level IV NICU infants should receive rGS.

Key findings from the 408-infant study showed that 49.2% of infants in the interventional group received a precise genetic diagnosis (PrGD), compared to 9.7% in conventional care. The study revealed that 42% of diagnosed infants would have been missed using conventional protocols, with 69% being non-white. The new approach led to clinical management changes in nearly 97% of diagnosed cases.

GeneDx also announced the launch of ultraRapid Whole Genome Sequencing, offering results in as soon as 48 hours for NICU and PICU patients, and integration with Epic Aura to streamline genetic diagnoses delivery.

GeneDx (WGS) has announced the launch of ultraRapid Whole Genome Sequencing, delivering genomic insights for NICU and PICU patients in as fast as 48 hours. This accelerated testing addresses the critical underutilization of genetic testing in NICUs, where up to 25% of patients likely have genetic disorders, yet less than 5% undergo testing.

The service, available for ordering in March through the GeneDx portal and Epic Aura integration, can lead to healthcare savings exceeding $15,000 per child by reducing unnecessary treatments and shortening NICU stays. Without genetic diagnosis, NICU stays are typically 15-20 days longer. The company's advanced technology and experience in sequencing over 750,000 exomes and genomes enables efficient testing at scale.

Genetic diseases are the leading identifiable cause of infant death, and genetic diagnosis can impact clinical management for more than 60% of critically ill infants.

GeneDx (Nasdaq: WGS), a leader in genomic insights and health outcomes, has announced its participation in the 45th Annual TD Cowen Health Care Conference in Boston, MA, from March 3-5, 2025. The company's management will engage in a fireside chat on March 4, 2025, at 1:10 p.m. ET.

The presentation will be accessible through a live and archived webcast on the company's investor relations website. GeneDx specializes in translating complex genomic data into clinical solutions through their industry-leading exome and genome tests, supported by one of the world's largest rare disease data sets. Their mission focuses on delivering personalized medical care through genetic diagnosis, contributing to drug discovery advancement and healthcare system optimization.

GeneDx (WGS) announced its integration with Epic's specialty diagnostics suite, Aura, enabling health systems to order and receive genetic sequencing results directly within their electronic health records (EHR). UNC Health becomes the first health system to implement this integration, with additional health systems now able to access GeneDx's testing services including exome sequencing, whole genome sequencing, and rapid whole genome sequencing.

The integration streamlines the genetic testing process, making results more accessible and visible within patient records. GeneDx has significant experience in genetic testing, having sequenced over 750,000 exomes and genomes, and maintains one of the largest rare disease data sets. The company's services are trusted by 8 out of 10 genetics experts for exome and genome testing.